コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ed with either a glial toxin or an adenosine A1 receptor antagonist.
2 protein kinase A inhibitor and an adenosine A1 receptor antagonist.
3 nized by 8-phenyltheophylline (1 microM), an A1 receptor antagonist.
4 clopentyl-1,3,-dipropylxanthine (DPCPX), the A1 receptor antagonist.
5 eizures, a known potential adverse effect of A1-receptor antagonists.
6 ion in mutants much more effectively than an A(1) receptor antagonist.
8 lfophenyl theophylline or with the selective A1-receptor antagonist 1,3-dipropyl, 8-cyclopentylxanthi
9 inal fluid (aCSF) and two doses of adenosine A(1) receptor antagonist, 1,3-dipropyl-8-phenylxanthine
10 sine receptor agonists but adenosine A(2) or A(1) receptor antagonists 3,7-dimethyl-1-propargyl xanth
11 ion were abolished or prevented by adenosine A1 receptor antagonists (50 mumol/L theophylline/1 mumol
12 tion of MMP-2 was inhibited by the adenosine A(1) receptor antagonist 8-cyclopentyl-1,3-dimethylxanth
13 yl-adenosine (CPA, 10 nM) and blocked by the A(1) receptor antagonist 8-cyclopentyl-1,3-dipropylxanth
14 were not altered by the selective adenosine A(1) receptor antagonist 8-cyclopentyl-1,3-dipropylxanth
15 oxic response, is inhibited by the adenosine A(1) receptor antagonist 8-cyclopentyl-1,3-dipropylxanth
16 36X-mediated inhibition was abolished by the A(1) receptor antagonist 8-cyclopentyl-1,3-dipropylxanth
17 t 8-sulphophenyltheopylline (8-SPT), nor the A(1) receptor antagonist 8-cyclopentyl-1,3-dipropylxanth
21 0.9%) by systemic injection of the adenosine A1 receptor antagonist 8-CPT (2.5 mg kg(-1)) approximate
22 ly reversed in the presence of the adenosine A1 receptor antagonist 8-cyclopentyl-1, 3-dipropylxanthi
24 ibitor l-NAME (Group 1, n = 8) and adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthin
26 s a mediator of IPC, the selective adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthin
30 her adenosine deaminase or DMPX, but not the A1 receptor antagonist 8-cyclopentyl-dipropylxanthine, s
31 pargylxanthine (DMPX), but unaffected by the A1-receptor antagonists 8-cyclopentyl-1,3-dipropylxanthi
32 xogenous adenosine, or a selective adenosine A1 receptor antagonist (8-cyclopentyl-1, 3-dimethylxanth
33 d in preparations treated with the adenosine A(1) receptor antagonist, 8-cyclopentyl-1,3-dimethylxant
34 an effect that was blocked by the adenosine A(1) receptor antagonist, 8-cyclopentyl-1,3-dipropylxant
35 of SPWs in slices treated with an adenosine A1 receptor antagonist, a finding that links the present
36 ling, readily repeatable, and was blocked by A1 receptor antagonists and by adenosine deaminase, sugg
38 the administration of a selective adenosine A1 receptor antagonist but not by a selective adenosine
39 y 1,3-dipropyl-8-cyclopentylxanthine, an Ado A1 receptor antagonist, but was unaffected by 3,7-dimeth
41 Since the sleep-suppressing effects of the A1 receptor antagonist CPT were prevented following inhi
42 or administration of the selective adenosine A1 receptor antagonist dipropylcyclopentylxanthine (DPCP
43 reathing 12 and 8 % O(2) were reduced by the A(1) receptor antagonist DPCPX, by 60 and 40 %, respecti
44 arge induced by adenosine was blocked by the A1 receptor antagonist DPCPX (10 microM) but remained un
45 ould be inhibited by the selective adenosine A1 receptor antagonist DPCPX (300 microg/kg; P < 0.05).
46 fter administration of a selective adenosine A1 receptor antagonist DPCPX (8-cyclopentyl-1,3-dipropyl
47 .4 nM for antagonism of CPA by the adenosine A1 receptor antagonist DPCPX (8-cyclopentyl-1,3-dipropyl
49 LTF (85 +/- 11%, P < 0.05), but an adenosine A(1) receptor antagonist (DPCPX, 3 microg kg(-1), 10 mic
50 F and volume overload, KW-3902, an adenosine A1-receptor antagonist, enhances the response to loop di
52 Pertinent to this, brief applications of A1 receptor antagonists immediately after theta stimulat
53 o characterization of a dual adenosine A(2A)/A(1) receptor antagonist in several animal models of Par
55 haracterization of two, dual adenosine A(2A)/A(1) receptor antagonists in several animal models of Pa
56 quantified after microinjecting an adenosine A(1) receptor antagonist into the prefrontal cortex.
58 acerebroventricular infusion of an adenosine A1 receptor antagonist produced a similar decrease in se
60 Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospital
61 Compounds 13 and 14 are potent dual A(2A)/A(1) receptor antagonists that have excellent activity,
62 ble to that of BG9928, a selective adenosine A1 receptor antagonist that is currently in clinical tri
63 ropylxanthine (DPCPX), a selective adenosine A1 receptor antagonist that is permeable to the blood br
64 Imidazoline 14 is a competitive adenosine A1 receptor antagonist with a pA2 value of 8.88 and is h
65 (4H)-one, is a particularly potent adenosine A1 receptor antagonist with good selectivity over the ot
67 is that the use of rolofylline, an adenosine A1-receptor antagonist, would improve dyspnea, reduce th
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。